Adalimumab biosimilar - Beijing Eastern Biotech
Alternative Names: JY026Latest Information Update: 31 Dec 2021
At a glance
- Originator Beijing Eastern Biotech
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 09 Sep 2020 Early research in Autoimmune disorders in China (Parenteral) before September 2020 (Beijing Eastern Biotech pipeline, September 2020)